Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

61. MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy

MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy Mucositis Guidelines MASCC Membership MASCC Meetings Practice Resources Publications Study Groups News ISOO Help MASCC Membership MASCC Meetings Practice Resources Publications Study Groups News ISOO Help MASCC/ISOO Mucositis Clinical Practice Guidelines ©MASCC, Multinational Association for Supportive Care in Cancer™ • All rights reserved worldwide. 2019 Guidelines Update - July 2019 MASCC (...) is pleased to announce the latest update of the MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy . MASCC’s Mucositis Study Group published an editorial and seven articles in a Special Section of Supportive Care in Cancer in July, 2019. The papers are available via open access until August 8, 2020. (Please log in below for links to the papers.) This is the first set of papers generated as part of this guideline update, and it represents several types

2019 International Society for Oral Oncology

62. Colorectal Cancer Screening Evidence Brief

Colorectal Cancer Screening Evidence Brief 1 Age to Initiate Colorectal Cancer Screening in Average Risk Individuals: Evidence Brief, June 2019 Key Points • Colorectal cancer incidence and mortality are increasing in individuals under age 50. • Simulation models suggest there may be benefit to screening average risk patients beginning at age 45, but it is unclear if this benefit outweighs the risks of screening • Patients age 45-49 who express interest in screening should be engaged in shared (...) -decision making to discuss the risks and benefits • It is strongly recommended that all average risk patients 50 years and older should be screened for colon cancer • Extra vigilance for symptoms and risk factors of colon cancer (including family history in people aged 45-49) is advised given increasing colorectal cancer rates in this group. Definition of Average Risk This guidance applies to individuals at average risk for colorectal cancer. Patients not considered average risk include those

2019 Institute for Clinical Systems Improvement

63. Updated treatment recommendations for Early Colon Cancer

Updated treatment recommendations for Early Colon Cancer Early Colon Cancer Treatment Recommendations | ESMO Welcome to the EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY , the leading European professional organisation for medical oncology. Search Careers at ESMO ESMO Oncology Journals Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates.​ Connect with ESMO Discover ESMO's new social (...) guidelines, including the latest CPG publications, updated recommendations, algorithms, pocket guidelines and MCBS grading ESMO Guidelines Slide Sets Quick and easy access to the essential content of the guidelines – PowerPoint slides and PDFs including algorithms, figures and tables – free to download Breast Cancer Early Breast Cancer • 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4) • Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian

2019 European Society for Medical Oncology

64. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis

Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis It is unclear if direct oral anticoagulant (DOAC) is efficacious and safe for prophylaxis of venous thromboembolism (VTE) in ambulatory patients with cancer.We performed a systematic review using EMBASE, MEDLINE, and CENTRAL. Inclusion criteria included adult ambulatory patients with cancer, prophylactic use of DOAC, and randomized controlled trials. Exclusion (...) with high-risk Khorana score (3+) derived the largest absolute risk reduction of VTE.Low-dose DOAC reduces the rate of overall VTE in higher risk cancer patients starting systemic chemotherapy. It may reduce the rate of symptomatic VTE but increase the likelihood of bleeding.© 2019 International Society on Thrombosis and Haemostasis.

2019 EvidenceUpdates

65. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We updated the analysis to investigate patterns of recurrence and did a post-hoc survival analysis.In the multicentre randomised phase (...) 3 PORTEC-3 trial, women with high-risk endometrial cancer were eligible if they had International Federation of Gynaecology and Obstetrics (FIGO) 2009 stage I, endometrioid grade 3 cancer with deep myometrial invasion or lymphovascular space invasion, or both; stage II or III disease; or stage I-III disease with serous or clear cell histology; were aged 18 years and older; and had a WHO performance status of 0-2. Participants were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy

2019 EvidenceUpdates

66. Laparoscopic Versus Open Complete Mesocolon Excision in Right Colon Cancer: A Systematic Review and Meta-Analysis

Laparoscopic Versus Open Complete Mesocolon Excision in Right Colon Cancer: A Systematic Review and Meta-Analysis Laparoscopic complete mesocolon excision (LCME) for right colonic cancer improves oncological outcomes. This systematic review and meta-analysis aimed to compare intraoperative, postoperative, and oncological outcomes after LCME and open total mesocolon excision (OCME) for right-sided colonic cancers.Literature searches of electronic databases and manual searches up to January 31 (...) to 4.12, p = 0.03) and distant recurrence (OR = 1.63, 95% CI 1.23-2.16, p = 0.0008). There was no significant difference regarding mortality, anastomosis leakage, number of harvested lymph nodes, and 3-year disease-free survival. Open approach was significantly better than laparoscopy in terms of operative time (MD = - 34.76 min, 95% CI - 46.01 to - 23.50, p < 0.00001) and chyle leakage (OR = 0.41, 95% CI 0.18 to 0.96, p = 0.04).This meta-analysis suggests that LCME in right colon cancer surgery

2019 EvidenceUpdates

67. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update This overview presents the updated European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ (CIS).To provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation and recommendations.A broad and comprehensive scoping exercise covering all areas of the NMIBC (...) biopsies in CIS. In papillary lesions, a complete TURB is essential for the patient's prognosis and correct diagnosis. Where the initial resection is incomplete, where there is no muscle in the specimen, or where a T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risks of both recurrence and progression may be estimated for individual patients using the European Organisation for Research and Treatment of Cancer (EORTC) scoring system. Stratification of patients into low

2019 EvidenceUpdates

68. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer.PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs published from August 1, 2014, through December 4, 2018. ASCO convened an Expert Panel to review the evidence and revise previous recommendations (...) as needed.The systematic review included 35 publications on VTE prophylaxis and treatment and 18 publications on VTE risk assessment. Two RCTs of direct oral anticoagulants (DOACs) for the treatment of VTE in patients with cancer reported that edoxaban and rivaroxaban are effective but are linked with a higher risk of bleeding compared with low-molecular-weight heparin (LMWH) in patients with GI and potentially genitourinary cancers. Two additional RCTs reported on DOACs for thromboprophylaxis in ambulatory

2019 EvidenceUpdates

69. Post-polypectomy and post-colorectal cancer resection surveillance guidelines

Post-polypectomy and post-colorectal cancer resection surveillance guidelines 1 | P a g e BSG/ACPGBI/PHE Post-polypectomy and post-colorectal cancer resection surveillance guidelines Title page Lead author & corresponding author: Professor Matthew D. Rutter Professor of Gastroenterology (1) University Hospital of North Tees, Stockton-on-Tees, TS19 8PE, UK (address for correspondence) (2) Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne, UK Matt.rutter@nth.nhs.uk +44 (0 (...) Research (ScHARR), University of Sheffield, Sheffield, UK Mrs Barbara Hibbert Lay representative Mr John Marsh Lay representative Dr Billie Moores National Lead Screening QA Service Public Health England, London, UK Dr Amanda Cross (co-senior author) Head of the Cancer Screening and Prevention Research Group Imperial College London, UK Professor Linda Sharp (co-senior author) Professor of Cancer Epidemiology Institute of Health & Society, Newcastle University, Newcastle-upon-Tyne, UK Word count: 19168

2019 British Society of Gastroenterology

70. Guidelines for the management of hereditary colorectal cancer

Guidelines for the management of hereditary colorectal cancer Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/ Association of Coloproctologists of Great Britain and Ireland (ACPGBI)/ United Kingdom Cancer Genetics Group (UKCGG) Authors *Kevin J Monahan, BSG, Consultant Gastroenterologist, Family Cancer Clinic, St Marks Hospital, Harrow, London; Department of Surgery and Cancer, Imperial College, London. Malcolm Dunlop, ACPGBI (...) Kaur, Patient representative, Bowel Cancer UK. Fiona Lalloo, UKCGG, Consultant Clinical Geneticist, Manchester Centre for Genomic Medicine. Andrew Latchford, BSG, Consultant Gastroenterologist, St Marks Hospital, Harrow, London; Department of Surgery and Cancer, Imperial College, London. Matthew D Rutter, BSG, Consultant Gastroenterologist, University Hospital of North Tees, Stockton on Tees, UK; Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK. Bianca De Souza

2019 British Society of Gastroenterology

71. Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer

Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer Guideline 1-14 Version 3 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer A. Arnaout, N. Varela, M. Allarakhia, L. Grimard, A. Hey, J. Lau, L. Thain, A. Eisen, and the Staging in Early Stage Breast Cancer Advisory Committee 1 Report Date: October 7, 2019 (...) (Vancouver Style): Arnaout A, Varela NP, Allarakhia M, Grimard L, Hey A, et al. Baseline staging imaging for distant metastasis in women with stage I, II, and III breast cancer. Toronto (ON): Cancer Care Ontario; 2019 October 7. Program in Evidence- Based Care Guideline No.: 1-14 Version 3. Copyright This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves

2019 Cancer Care Ontario

72. Metastatic Breast Cancer Summary

Metastatic Breast Cancer Summary Metastatic breast cancer Breast cancer is the most common cancer diagnosed in Australia. Approximately 5% of patients diagnosed with breast cancer in Australia have metastatic disease at initial breast cancer diagnosis (NCCI, Cancer Australia), and some patients who have early breast cancer at diagnosis will have a recurrence that is metastatic. However exact statistics on patients with metastatic breast cancer in Australia are not currently available (...) . For patients with metastatic breast cancer at diagnosis in Australia, 5-year relative survival is low at 32%, compared with over 95% for patients with early breast cancer. While many patients with metastatic breast cancer are living longer, current treatments for metastatic breast cancer are generally not curative. The main treatment goals for metastatic breast cancer are to effectively manage symptoms and optimise quality of life, as well as to prolong survival. There can be emotional, physical

2019 Cancer Australia

73. Abemaciclib (Verzenio) - Metastatic Breast Cancer

Abemaciclib (Verzenio) - Metastatic Breast Cancer Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you

2019 Health Canada - drugs and medical devices

74. The association between cancer outcomes and time intervals to diagnosis and treatment

The association between cancer outcomes and time intervals to diagnosis and treatment SHTG Evidence Synthesis | 1 Evidence Synthesis Number 05 October 2019 In response to an enquiry from the Scottish Government Cancer Waiting Times Review Implementation Group The association between cancer outcomes and time intervals to diagnosis and treatment What were we asked to look at? To inform an ongoing clinical review of cancer waiting times in Scotland we were asked to summarise the published evidence (...) on the association between time intervals to diagnosis and treatment and cancer outcomes. Why is this important? It is important to understand the likely impact of variations in cancer waiting times across various cancer types to help ensure optimal outcomes for patients and inform planning and policy for cancer services in Scotland. What was our approach? This Evidence Synthesis provides an update to a comprehensive 2015 systematic review of time to diagnosis and treatment and its effects on cancer outcomes

2019 SHTG Advice Statements

75. Triptorelin acetate (Decapeptyl) - breast cancer

Triptorelin acetate (Decapeptyl) - breast cancer 1 Published 7 October 2019 1 SMC2186 triptorelin sustained-release 3mg powder for suspension for injection (Decapeptyl SR®) Ipsen Ltd. 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission triptorelin (Decapeptyl SR ® (...) ) is accepted for use within NHSScotland. Indication under review: As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy. In premenopausal women with early breast cancer at high risk of recurrence, ovarian suppression (provided by triptorelin, oophorectomy or radiation ablation) plus an aromatase inhibitor increased disease free

2019 Scottish Medicines Consortium

76. Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines

Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines Last updated: August 1, 2019 Project Number: RA1056-000 Product Line: Research Type: Drug Report Type (...) : Reference List Result type: Report Question What is the clinical effectiveness of nivolumab, pembrolizumab, or ipilimumab-nivolumab in patients with melanoma who progressed after adjuvant therapy with nivolumab or pembrolizumab? What is the clinical effectiveness of atezolizumab, nivolumab or pembrolizumab in patients with recurrent/metastatic non-small cell lung cancer (NSCLC) who progressed after consolidation therapy with durvalumab? What are the evidence-based guidelines on the timing of retreatment

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

77. Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines

Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines | CADTH.ca Find the information you need Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines Last updated: April 24, 2019 Project Number: RC1103-000 Product Line: Research Type: Devices and Systems (...) Report Type: Summary with Critical Appraisal Result type: Report Question What are the evidence-based guidelines regarding methods for sentinel lymph node biopsy for the management of breast cancer? Key Message Five evidence-based guidelines were identified. SLNB is recommended for axillary staging for patients with early-stage or invasive breast cancer without clinically or pathologically positive lymph nodes. SLNB is recommended in patients with ductal carcinoma in situ (DCIS) when mastectomy

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

78. Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details

Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details | CADTH.ca Find the information you need Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Project Number pCODR 10158 Brand Name Mvasi Generic Name Bevacizumab Strength 100 mg and 400 mg Tumour (...) Type Gastrointestinal / Lung Indication Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar Funding Request For first-line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with fluoropyrimidine based chemotherapy / For treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen Review Status Final Biosimilar Dossier Issued Pre

2019 CADTH - Pan Canadian Oncology Drug Review

79. Tagrisso for Non-Small Cell Lung Cancer (first line) – Details

Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Tagrisso for Non-Small Cell Lung Cancer (first line) – Details | CADTH.ca Find the information you need Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Project Number pCODR 10137 Brand Name Tagrisso Generic Name Osimertinib Strength 40 mg and 80 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer (first line) Funding Request For the first-line (...) treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date July 10, 2018 Manufacturer AstraZeneca Canada Inc. Sponsor AstraZeneca Canada Inc. Submission Date May 16, 2018 Submission Deemed Complete May 24, 2018 Submission Type New Indication Prioritization Requested Requested and Not Granted Stakeholder Input Deadline ‡ May

2019 CADTH - Pan Canadian Oncology Drug Review

80. Kisqali for Advanced or Metastatic Breast Cancer – Details

Kisqali for Advanced or Metastatic Breast Cancer – Details Kisqali for Advanced or Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Kisqali for Advanced or Metastatic Breast Cancer – Details Kisqali for Advanced or Metastatic Breast Cancer – Details Project Number pCODR 10194 Brand Name Kisqali Generic Name Ribociclib Tumour Type Breast Indication Advanced or Metastatic Breast Cancer Funding Request In combination with an aromatase inhibitor (AI) and a luteinizing (...) hormone releasing hormone (LHRH) agonist for the treatment of pre/peri- menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Novartis Pharmaceuticals Canada Inc. Sponsor Novartis Pharmaceuticals Canada Inc. Submission Date August 26, 2019 Submission Deemed Complete September 10, 2019 Submission Type

2019 CADTH - Pan Canadian Oncology Drug Review